JP2018525353A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525353A5 JP2018525353A5 JP2018500463A JP2018500463A JP2018525353A5 JP 2018525353 A5 JP2018525353 A5 JP 2018525353A5 JP 2018500463 A JP2018500463 A JP 2018500463A JP 2018500463 A JP2018500463 A JP 2018500463A JP 2018525353 A5 JP2018525353 A5 JP 2018525353A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- phenyl
- alkoxy
- independently selected
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 80
- 150000003839 salts Chemical class 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 47
- -1 (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl Chemical group 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 17
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 100
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 39
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 21
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 17
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 16
- 125000005843 halogen group Chemical group 0.000 claims 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 10
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 9
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims 8
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000006413 ring segment Chemical group 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000004043 oxo group Chemical group O=* 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 4
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000003132 pyranosyl group Chemical group 0.000 claims 3
- 230000037390 scarring Effects 0.000 claims 3
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004924 2-naphthylethyl group Chemical group C1=C(C=CC2=CC=CC=C12)CC* 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 102000004152 Bone morphogenetic protein 1 Human genes 0.000 claims 2
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 241000189705 Dunedin group Species 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 101000637851 Homo sapiens Tolloid-like protein 1 Proteins 0.000 claims 2
- 101000637850 Homo sapiens Tolloid-like protein 2 Proteins 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 102100031996 Tolloid-like protein 1 Human genes 0.000 claims 2
- 102100031997 Tolloid-like protein 2 Human genes 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004220 muscle function Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 0 C*1OCCC(C)(C)Oc(ccc(C)c2)c2OCC1 Chemical compound C*1OCCC(C)(C)Oc(ccc(C)c2)c2OCC1 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562190345P | 2015-07-09 | 2015-07-09 | |
| US62/190,345 | 2015-07-09 | ||
| PCT/IB2016/054123 WO2017006296A1 (en) | 2015-07-09 | 2016-07-08 | N-hydroxyformamide compounds and compositions comprising them for use as bmp1, tll1 and/or tll2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018525353A JP2018525353A (ja) | 2018-09-06 |
| JP2018525353A5 true JP2018525353A5 (https=) | 2019-08-22 |
Family
ID=56799500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018500463A Pending JP2018525353A (ja) | 2015-07-09 | 2016-07-08 | Ｂｍｐ１、ｔｌｌ１および／またはｔｌｌ２の阻害剤としての使用するための、ｎ−ヒドロキシホルムアミド化合物およびそれらを含んでなる組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20180362485A1 (https=) |
| EP (1) | EP3319961A1 (https=) |
| JP (1) | JP2018525353A (https=) |
| TW (1) | TW201716390A (https=) |
| WO (1) | WO2017006296A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA39171A1 (fr) | 2014-01-10 | 2017-07-31 | Glaxosmithkline Intellectual Property (No 2) Ltd | Dérivés d'hydroxy formamide et leur utilisation |
| EP4484444A1 (en) | 2023-06-28 | 2025-01-01 | Centre National de la Recherche Scientifique | Protein and fragments thereof, and their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010080709A (ko) * | 1998-12-10 | 2001-08-22 | 프리돌린 클라우스너, 롤란드 비. 보레르 | 프로콜라겐 ｃ-프로티나제 저해제 |
| AU2003296960A1 (en) * | 2002-12-11 | 2004-06-30 | Smithkline Beecham Corporation | Peptide deformylase inhibitors |
| EP2518496A3 (en) | 2006-07-21 | 2013-02-27 | GENERA ISTRAZIVANJA d.o.o. | BMP-1 procollagen C-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders |
| CA2870365A1 (en) | 2012-04-25 | 2013-10-31 | Genera Istrazivanja D.O.O. | Methods and compositions for treating and diagnosing acute myocardial infarction |
| MA39171A1 (fr) | 2014-01-10 | 2017-07-31 | Glaxosmithkline Intellectual Property (No 2) Ltd | Dérivés d'hydroxy formamide et leur utilisation |
-
2016
- 2016-07-08 JP JP2018500463A patent/JP2018525353A/ja active Pending
- 2016-07-08 US US15/736,911 patent/US20180362485A1/en not_active Abandoned
- 2016-07-08 EP EP16756795.7A patent/EP3319961A1/en not_active Withdrawn
- 2016-07-08 WO PCT/IB2016/054123 patent/WO2017006296A1/en not_active Ceased
- 2016-07-11 TW TW105121791A patent/TW201716390A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528889A5 (https=) | ||
| JP2010524963A5 (https=) | ||
| JP2017518959A5 (https=) | ||
| JP2020537657A5 (https=) | ||
| JP2019519598A5 (https=) | ||
| JP2020502047A5 (https=) | ||
| JP2019535672A5 (https=) | ||
| JP2019094350A (ja) | 抗癌活性及び抗増殖活性を呈する２−アミノピリミジン−６−オン及び類似体 | |
| JP2014015465A5 (https=) | ||
| CA2540163A1 (en) | Thrombin receptor antagonists | |
| JP2013510825A5 (https=) | ||
| JP2016121196A5 (https=) | ||
| JP2009534407A5 (https=) | ||
| JP2009544602A5 (https=) | ||
| HRP20240157T1 (hr) | Deuterirani derivati lanifibranora | |
| UA104997C2 (uk) | Аміди азотвмісних насичених гетероциклів та 3,5-діаміно-6-хлор-2-піразинкарбонової кислоти як лікарський засіб | |
| JP2019531279A5 (https=) | ||
| JP2020521766A5 (https=) | ||
| MA38935B1 (fr) | Dérivés de diazacarbazole à titre de ligands tau-pet | |
| MX2023013233A (es) | Derivados de piridina con sustituyentes ciclicos ligados a n como inhibidores de cgas. | |
| JP2019535723A5 (https=) | ||
| JP2020502268A5 (https=) | ||
| JP2016532669A5 (https=) | ||
| JP2018525353A5 (https=) | ||
| JP2021528451A5 (https=) |